RecruitingInterventionalPhase 2Last updated Jan 6, 2026

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

A Phase 2 Study of Epcoritamab as a Consolidation Therapy for 2nd Generation BTKi +/- Obinutuzumab in CLL/SLL Patients or Variants of This.

Overview

ClinicalTrials.gov ID: NCT07108998
Lead Sponsor: Zulfa OmerOTHER
Brief Summary: This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.
Study Type: Interventional

Status

Overall Status: Recruiting
Start Date: Aug 22, 2025Actual
Primary Completion Date: Jul 1, 2027Estimated
Completion Date: Jul 1, 2029Estimated

Study Record Dates

First Submitted: Jul 21, 2025
First Submitted that Met QC Criteria: Jul 30, 2025
First Posted: Aug 7, 2025Actual
Last Update Submitted that Met QC Criteria: Jan 2, 2026
Last Update Posted: Jan 6, 2026Actual
Last Verified: Jan 2026

NCT06811272Recruiting

Outpatient Epcoritamab in Large B-cell Lymphoma

NCT06414148Recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

NCT06919939Recruiting

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

NCT06796998Recruiting

Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

NCT06931652Recruiting

Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

NCT05451810Active, not recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma